Paris, France
Research view
Duchenne muscular dystrophy: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.
- All targets
- DMD 9
- ATM 0
- SIRT1 0
- EGFR 0
- AMPK 0
- HDAC 0
- mTOR 0
- SGLT2 1
- TNF 0
- CFTR 1
- CTLA-4 0
- G6PD 0
- GLP-1 0
- HTT 1
- IL-23 0
- IL-6 0
- NF1 1
- NRF2 0
- PINK1 0
- PPAR 0
- SMN1 1
- STK11 0
- TTR 1
- YAP 0
EU-13 is a filter, not a ranking: it only narrows the list.
Newcastle upon Tyne, United Kingdom
Leiden, Netherlands
Columbus, United States
Columbus, United States
Cincinnati, United States
Paris, France
Gif-sur-Yvette, France
Nashville, United States
Paris, France
Cincinnati, United States
Rome, Italy
Ottawa, Canada
Gainesville, United States
Milan, Italy
Paris, France
London, United Kingdom
Philadelphia, United States
Paris, France
Philadelphia, United States
Ottawa, Canada
Paris, France
Little Rock, United States
Cambridge, United States
24 of 390 institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Terminated
“Study is being terminated due to a business decision.”Registry text, quoted unchanged. Source
Terminated
“Sponsor decision”Registry text, quoted unchanged. Source
Terminated
Gut Peptides and Bone Remodeling in Children With Neuromuscular Disorders
“Terminated since further recruitment proved difficult”Registry text, quoted unchanged. Source
Terminated
“PGN-EDO51 development terminated by Sponsor”Registry text, quoted unchanged. Source
Withdrawn
Natural History of Duchenne Muscular Dystrophy Cardiomyopathy (DMD-CMP)
“Cancellation of financing by the financier.”Registry text, quoted unchanged. Source
Terminated
“All participants who have received fordadistrogene movaparvovec in any Pfizer study will now be assessed for long-term safety in 1 combined study: C3391003”Registry text, quoted unchanged. Source
Terminated
Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy
“All participants who have received fordadistrogene movaparvovec in any Pfizer study will now be assessed for long-term safety in one combined study: C3391003”Registry text, quoted unchanged. Source
Terminated
“All participants who have received fordadistrogene movaparvovec in any Pfizer study will now be assessed for long-term safety in 1 combined study: C3391003”Registry text, quoted unchanged. Source
Terminated
“Study is being terminated due to a business decision.”Registry text, quoted unchanged. Source
Withdrawn
“Global PGN-EDO51 development voluntarily discontinued by Sponsor”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 2
- Organoids 3
- CRISPR-Cas Systems 13
- Gene Expression Profiling 7
- Sequence Analysis, RNA 1
- Whole Genome Sequencing 4
- Exome Sequencing 5
- Proteomics 13
- Metabolomics 1
- Mass Spectrometry 2
- Immunohistochemistry 3
- Magnetic Resonance Imaging 19
- Machine Learning 2
- Cohort Studies 8
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed. Machine-matched links are labelled.